CLINICAL TRIAL & CRO E&O INSURANCE
Professional Liability and Errors & Omissions coverage built for contract research organizations, sponsors, sites, IRBs, and clinical research professionals. Protection against protocol deviations, GCP violations, regulatory submission errors, and breach of professional duty allegations across all trial phases.
WHAT IS CLINICAL TRIAL & CRO E&O?
Professional Liability coverage that responds when a sponsor, subject, regulator, or third party alleges your clinical research services caused them harm.
CLINICAL TRIAL & CRO E&O INSURANCE — also called Contract Research Organization Professional Liability or Clinical Research E&O — protects CROs, clinical research sites, sponsor-investigators, IRBs, and clinical research professionals from claims arising out of their professional services. Coverage responds when a sponsor, subject, regulator, or third party alleges that an error, omission, protocol deviation, or compliance failure caused them financial loss.
Clinical research operates within a heavily regulated environment governed by FDA regulations, ICH-GCP guidelines, IRB oversight, sponsor protocols, and contractual obligations between dozens of parties. Standard insurance markets often decline clinical trial accounts entirely — the exposure mix combines Professional Liability, Products Liability, regulatory defense, and bodily injury risks that few generalist carriers will write. Specialty placement is essential.
The coverage typically pays DEFENSE COSTS, SETTLEMENTS, AND JUDGMENTS arising out of the rendering or failure to render clinical research professional services. Most policies are written on a CLAIMS-MADE basis with retroactive dates and extended reporting period options.
CLAIMS ACROSS THE TRIAL LIFECYCLE
Clinical research exposure spans every phase of development — from IND through post-marketing surveillance.
PRE-CLINICAL
SUBMISSION & SETUP
IND application errors, protocol design flaws, IRB submission issues, and informed consent drafting mistakes surface before enrollment begins.
PHASE I
SAFETY & DOSING
Adverse event reporting failures, dose escalation protocol deviations, and safety monitoring lapses generate claims during early-phase studies.
PHASE II
EFFICACY EVALUATION
Data integrity issues, randomization errors, blinding failures, and endpoint measurement disputes drive claims as efficacy data emerges.
PHASE III
PIVOTAL TRIALS
Multi-site coordination errors, data management failures, regulatory submission issues, and statistical analysis disputes drive high-stakes pivotal trial claims.
PHASE IV
POST-MARKETING
Post-marketing surveillance failures, registry data errors, real-world evidence disputes, and pharmacovigilance compliance issues drive long-tail claims.
WHAT CLINICAL TRIAL E&O TYPICALLY COVERS
Core protections built into a properly structured Clinical Research Professional Liability policy.
NEGLIGENCE CLAIMS
Defense and indemnity for alleged failure to use the standard of care expected of a clinical research professional.
PROTOCOL DEVIATIONS
Coverage for claims arising out of departures from approved study protocols, eligibility criteria errors, or study-conduct violations.
GCP / ICH VIOLATIONS
Defense for allegations of Good Clinical Practice violations, ICH guideline breaches, and regulatory compliance failures.
DATA INTEGRITY
Coverage for claims tied to data management errors, source document discrepancies, electronic data capture failures, or audit trail issues.
INFORMED CONSENT
Defense for claims arising out of informed consent drafting errors, failure to obtain proper consent, or re-consent failures during protocol amendments.
DEFENSE COSTS
Attorney fees, expert witnesses, court costs, and settlement negotiations — even for groundless suits.
PRIOR ACTS COVERAGE
Retroactive dates protect against claims for past trials and engagements — critical because trial-related claims can surface years after database lock.
REGULATORY DEFENSE
Sublimits available for FDA inspections, warning letter responses, EMA matters, and regulatory enforcement proceedings affecting research professionals.
CLINICAL RESEARCH STAKEHOLDER ECOSYSTEM
Professional liability exposure runs through every party to a clinical trial — coverage scales accordingly.
SPONSOR ROLE
CONTRACT RESEARCH ORGANIZATIONS
Full-service and functional CROs managing trial operations, data management, monitoring, and regulatory submissions on behalf of sponsors.
SPONSOR ROLE
PHARMACEUTICAL SPONSORS
Drug, biologic, and device sponsors conducting in-house clinical research or coordinating sponsor-investigator studies independently.
OVERSIGHT ROLE
INSTITUTIONAL REVIEW BOARDS
Independent and central IRBs providing ethical oversight, protocol review, informed consent approval, and ongoing study monitoring.
SITE ROLE
CLINICAL RESEARCH SITES
Independent research sites, site networks, and site management organizations conducting subject enrollment, study procedures, and data collection.
INVESTIGATOR ROLE
SPONSOR-INVESTIGATORS
Physician-researchers serving as both sponsor and principal investigator on investigator-initiated trials and academic research studies.
SUPPORT ROLE
SPECIALTY SERVICE PROVIDERS
Central laboratories, imaging providers, pharmacovigilance vendors, biostatistics firms, and other clinical specialty service providers.
GCP COMPLIANCE & FDA EXPOSURE
Good Clinical Practice violations and FDA enforcement deserve dedicated attention in any clinical trial E&O placement.
GCP, FDA & REGULATORY DEFENSE
Good Clinical Practice (GCP) compliance is the foundational regulatory framework governing every aspect of human subjects research. FDA inspections, warning letters, Form 483 observations, and regulatory enforcement actions can trigger sponsor disputes, contract claims, and significant defense costs — even when violations are administrative rather than substantive.
A properly structured Clinical Trial E&O policy provides defense for GCP violations, FDA enforcement matters, ICH-GCP compliance disputes, and regulatory submission errors. Coverage scope and sublimits vary significantly by carrier — making specialty broker placement essential for clinical research organizations.
CLINICAL RESEARCH OPERATIONS KIG WRITES
Coverage spans the full range of clinical research operations — from boutique specialty CROs to global service providers.
WHY CLINICAL RESEARCH FIRMS GET SUED
The recurring patterns that drive Clinical Trial & CRO E&O claim activity.
THE LARGEST SOURCES OF CLINICAL TRIAL CLAIMS include sponsor disputes over CRO performance and deliverables, regulatory enforcement findings traced to CRO compliance failures, data integrity issues discovered during sponsor audits, and study-conduct deviations identified during FDA inspections or sponsor monitoring visits.
Other recurring patterns include PROTOCOL AMENDMENT MANAGEMENT FAILURES, informed consent process errors, IRB approval lapses, vendor oversight breakdowns, and pharmacovigilance reporting deficiencies. Many claims arise during sponsor audits or following FDA inspection observations that trigger sponsor contractual review and dispute.
Documented standard operating procedures, robust quality management systems, defensible audit trails, and disciplined contract management form the first line of defense. A properly structured Clinical Trial E&O policy is the second.
REAL CLAIM SCENARIOS
How Clinical Trial & CRO E&O claims typically develop in practice.
PROTOCOL DEVIATION FINDINGS
An FDA inspection identified systematic protocol deviations across multiple sites managed by a CRO. The sponsor pursued the CRO under the master services agreement for remediation costs, regulatory response expenses, and data invalidation impact.
DATA INTEGRITY DISPUTE
A sponsor audit revealed source document discrepancies and EDC data entry errors at trial sites monitored by the CRO. The sponsor pursued the CRO for the cost of source data verification, database remediation, and resulting timeline delays.
INFORMED CONSENT FAILURE
A site failed to obtain proper re-consent following a protocol amendment. Subjects continued in the study under outdated consent forms. The sponsor and IRB pursued the site for the resulting regulatory findings and remediation requirements.
FDA WARNING LETTER
A CRO received a Form 483 followed by a warning letter citing GCP compliance failures. The sponsor terminated the master services agreement and pursued damages alleging breach of professional services obligations.
REGULATORY SUBMISSION ERROR
A regulatory consulting firm prepared an FDA submission containing material errors that delayed agency review and triggered a complete response letter. The sponsor pursued the firm for the cost of resubmission and resulting market entry delays.
CENTRAL LAB SAMPLE HANDLING
A central laboratory mishandled study samples, resulting in invalidated data points across multiple subjects. The sponsor pursued the lab for the cost of subject re-testing, data analysis impact, and timeline disruption.
RELATED COVERAGES & RESOURCES
Other coverages and reference pages that complement Clinical Trial & CRO E&O.
FREQUENTLY ASKED QUESTIONS
Common questions from CROs, sites, and clinical research professionals evaluating E&O coverage.
WHAT IS CLINICAL TRIAL & CRO E&O INSURANCE?
Clinical Trial E&O is Professional Liability coverage written specifically for contract research organizations and clinical research professionals. It responds to allegations that an error, omission, or failure in clinical research services caused a sponsor, subject, or third party financial harm.
DO CROs HAVE TO CARRY E&O?
Most pharmaceutical sponsor master services agreements contractually require minimum E&O limits as a condition of doing business. The level of coverage required typically scales with the size of the engagement and the therapeutic area's risk profile.
DOES CRO E&O COVER FDA REGULATORY MATTERS?
Many specialty Clinical Trial E&O policies provide affirmative defense for FDA inspections, Form 483 responses, warning letter matters, and related enforcement proceedings. Sublimit amounts and coverage triggers vary by carrier and should be reviewed before binding.
DOES CRO E&O COVER BODILY INJURY TO TRIAL SUBJECTS?
Bodily injury to clinical trial subjects is typically addressed by separate Clinical Trials Liability (CTL) or Subject Injury coverage — not E&O. Many CRO accounts carry both: E&O for professional services exposures, and CTL for subject injury obligations under sponsor protocols.
WHAT IS A CLAIMS-MADE POLICY?
A claims-made policy responds to claims first reported during the policy period — provided the work occurred after the retroactive date. Most Clinical Trial E&O policies are written claims-made.
WHY ARE RETROACTIVE DATES SO IMPORTANT FOR CROs?
Clinical trial claims often surface years after database lock, during sponsor audits, FDA inspections, or post-marketing surveillance reviews. The retroactive date determines whether work performed on completed studies remains covered when a claim eventually arrives.
WHAT IS TAIL COVERAGE?
Also called an Extended Reporting Period, tail coverage extends the time you can report claims after a claims-made policy expires. Critical when changing carriers, completing major engagements, dissolving an entity, or transitioning between corporate structures.
DOES CRO E&O COVER INTERNATIONAL TRIALS?
Coverage for international clinical research operations varies by policy form. Many specialty policies provide global territorial coverage for professional services rendered worldwide; some restrict coverage geographically or require disclosure of international site locations and regulatory authorities involved.
WHAT DOES CRO E&O NOT COVER?
Common exclusions include criminal acts, fraud, intentional wrongdoing, known prior acts, return of fees, bodily injury to subjects (covered by CTL/Subject Injury instead), product liability of the investigational product (covered by sponsor's product liability), and acts outside the scope of professional research services. Specific exclusions vary by policy form.
WHY USE A SPECIALTY BROKER FOR CLINICAL TRIAL E&O?
Clinical Trial E&O is one of the most specialized markets in the Professional Liability space — many standard markets decline outright. A specialty broker accesses E&S markets that affirmatively write CRO and clinical research risk, compares retroactive dates, exclusions, regulatory defense sublimits, territorial coverage, and tail options to place coverage that fits the operation.